13th U.S. AI patent awarded to Mauna Kea
Expanded patent portfolio boosts platform value, supports strategic partnerships
PARIS & BOSTON–(BUSINESS WIRE)–Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has been granted a new U.S. patent for real-time AI-based enhancement of Confocal Laser Endomicroscopy (CLE), significantly reinforcing its intellectual property.
This new technology represents an innovative solution for interfacing a real-time AI-assisted version of Cellvizio with physicians, taking into account the cognitive and user experience constraints specific to diagnostic procedures. This cutting-edge technology aims to improve user experience and efficiency of AI-integrated endomicroscopy in clinical settings.
This new patent1, codenamed “AURA”, complements Mauna Kea’s existing “EVA” (Endomicroscopy Virtual Assistant) portfolio, which already comprises 12 patents dedicated to AI-based innovative multistage image processing architectures and workflows.
The combined capabilities of AURA and EVA are expected to significantly enhance the usability, interface, and effectiveness of Mauna Kea’s Cellvizio CLE technology, improving physicians’ ability to adopt and use Cellvizio across various medical specialties. This achievement builds on Mauna Kea’s recent partnership with the UK-based company V7, a leading AI and data labeling company, announced in March 2024, which focuses on building large, high-quality annotated endomicroscopy datasets.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies commented: “Since the launch of Cellvizio, Mauna Kea has strategically invested in machine learning capabilities – including the “Smart Atlas” project in 2010 – and its related intellectual property. We are making significant progress on our AI roadmap and obtaining our 13th patent on this key topic is a major and timely milestone. The synergy between our expanding patent portfolio, including AURA and EVA, and our recent partnerships creates a rich ecosystem for advancing AI, in multiple therapeutic areas, including early-stage esophageal cancer detection, pancreatic cyst characterization and Inflammatory Bowel Disease. This approach positions Mauna Kea at the forefront of AI-assisted in vivo cellular imaging enabling improved treatment and outcomes.”
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
